A serum metabolite panel predicts Crohn’s disease relapse in patients discontinuing infliximab and continuing antimetabolite therapy: sub-analysis of the SPARE Trial

This is a publication. If there is no link to the publication on this page, you can try the pre-formated search via the search engines listed on this page.

Authors: D Radford-Smith, J Satsangi, E Louis, D Laharie, N Ding, B Siegmund, G D’Haens, H Erik, A Yates, D Anthony, J F Colombel, F Probert GETAID and the SPARE-Biocycle research group

Journal title: Journal of Crohn's and Colitis

Journal number: 16(1)

Journal publisher: Oxford Academic

Published year: 2022

Published pages: i458-i460

DOI identifier: 10.1093/ecco-jcc/jjab232.621